BUY Cohance Lifesciences Limited — BOB Capital Markets
byBOB Capital MarketsHorizon: NA (inferred 1 year)14 Aug 2025via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Cohance Lifesciences Stock Jumps Over 2% Despite Poor Q1 Earnings; Here's Why
NewsNdtv-Profit·6 Aug · 1w ago
1 other SEBI-registered advisor has an active long-term BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·6 Aug · 1w ago
Cohance Lifesciences’ Hyderabad plant gets USFDA observations: What it means for the pharma maker
NewsCnbc-Tv18·5 Aug · 1w ago
Cohance Lifesciences Limited announced its unaudited financial results for Q1FY27, reporting revenue of ₹4,223 million (down 23.1% YoY) and adjusted EBITDA of ₹92 million. The company expects a reboun
NSE · Press Release·5 Aug · 1w ago
Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·5 Aug · 1w ago
Cohance Lifesciences Q1 Review: Brokerages Split After Earnings Slump — Check Potential Upside, Target Price
NewsNdtv-Profit·6 Aug · 1w ago
1 other SEBI-registered advisor has an active long-term SELL call on this stock, issued in the last 14 days
Advisor consensus · same horizon·6 Aug · 1w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.